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Cutaneous melanoma is a heterogeneous cancer that va-
ries in its clinical characteristics and genetic alterations. 
While general features like size can give clues to likely 
prognosis, histopathologic appearance remains the gold 
standard for assessing cutaneous melanoma. Numerous 
histopathologic subtypes have been described, but the 
most common are superficial spreading melanoma (SSM) 
(60–80%), nodular melanoma (NM) (around 15%) and 
lentigo maligna melanoma (LMM) (5–15%) (1, 2). Of 
these, NM has the poorest outcome.
There has long been debate over whether NM’s poor 
prognosis signifies a distinct, inherently ‘aggressive’ 
entity (3) or if it simply reflects higher median thickness 
at diagnosis than other subtypes (4, 5). While current 
international classification (6) favors the latter, there 
remains compelling evidence that NM is unique in its 
clustering of high-risk features such as high mitosis 
rates (7) and ulceration (8), and in its lethality (9). We 
undertook a detailed evaluation of NM as a possible 
histopathologic entity in a collaborative study between 
England and Australia. We hypothesised that if they were 
a distinctly aggressive subtype, then from the outset when 
relatively thin, primary NMs would be more mitotic than 
other subtypes of equal thickness. We further tested this 
hypothesis by estimating disease-free survival (DFS) 
rates according to histological subtype in subgroups of 
equal thickness among the Australian study patients.
METHODS
Patients aged 16–89 years, newly diagnosed with invasive, clinical 
stage IB or II cutaneous melanomas (6) in 2010–2014 were eligible 
for inclusion. In England, patients were ascertained at St George’s 
Hospital, London, with pathology review. In Australia, patients 
were diagnosed in primary care, regional or tertiary hospitals in 
Queensland (10). The study was approved by institutional ethics 
committees. 
Subtype, site, thickness (mm), mitotic rate (per mm2 or per 10 
hpf) and ulceration (present vs absent) were obtained from histo-
pathology reports. We classified tumor thickness as > 0 to 2 mm 
(no stage IA and too few stage IB tumors ≤ 1 mm for meaningful 
analysis), > 2 to 4, and > 4 mm, and mitotic rates per mm2 as < 1, 
1–< 2, 2 to 6, > 6 to give adequate numbers per category (n = 147 
(10%) had 0 mitoses). Outcomes for English patients were not 
available, but were obtained for all Australian patients to August 
31, 2017 via patient self-report, supplemented by systematic 
follow-up for melanoma recurrence or death in patients’ clinical 
records and the Queensland Cancer Registry. Differences in 
age, sex and histopathologic characteristics between melanoma 
patients diagnosed in England and Australia were assessed using 
chi-squared tests of homogeneity. Mean log-transformed mitotic 
rates of NMs adjusted for age, sex, thickness, ulceration, and 
country were compared with corresponding rates of SSM, LMM 
and ‘other’ (comprising unknown 55%, desmoplastic 14%, acral 
lentiginous 10%, naevoid 9%, other 11%) subtypes within catego-
ries of thickness. Differences between the adjusted least-squares 
means of log-transformed mitotic rates and between DFS rates 
were tested and analyses were performed in SAS 9.4.
RESULTS
There were 709 eligible patients with 724 melanomas 
diagnosed 2010–2014 in the English series (mean age 60 
years, 51% male) and 789 patients from Australia (mean 
age 62 years, 57% male). More melanomas occurred on 
the lower limb in England and head and neck in Austra-
lia (p < 0.003) and melanomas were thicker at diagnosis 
in England (3.15 ± 3.57 mm) than Australia (1.99 ± 1.67 
mm) (p < 0.0001). SSM comprised 57% and 43% of the 
English and Australian series, respectively, nodular 24% 
and 22%, LMM 3% in both, and other subtypes, 14% 
and 26% respectively (p < 0.0001). The two series were 
combined since the same factors were associated with 
NM in both (Table SI1), namely older age, male sex and 
head and neck location versus SSM, and thicknesses 
> 1 mm in relation to all subtypes (Table I). Ulcerated 
and highly mitotic (> 6 per mm2) melanomas were more 
likely to be nodular than another subtype. 
On average, the English melanoma patients had thicker 
lesions at diagnosis than the Australian patients (Table 
SII1) and this was also true for each sex (median 2.2 
mm vs 1.7 mm in males; 1.7 mm vs 1.3 mm in females). 
When mitosis rate was examined in relation to categories 
of thickness, thinner (≤ 2 mm) nodular subtypes had hig-
her rates than all other subtypes ≤ 2 mm and except for 
LMM, differences were significant (Table II, Table SII1). 
However for melanomas > 2 mm thick, there were no 
significant differences in mitosis rates between nodular, 
SSM or LMM subtypes; only remaining other subtypes 
had lower mitosis rates than NMs (Table II). 
Australian patients were followed-up after diagnosis 
for 2.9 to 6.9 years. Among those with known melanoma 
subtype whose melanomas were thinner (≤ 2 mm), DFS 
was 82% for NM, substantially worse than 91% for 
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SSM (p = 0.051) and 90% DFS for LMM (p = 0.089). In 
contrast, for melanomas > 2 mm thick, there were no sig-
nificant differences in DFS rates between nodular (66%), 
SSM (73%) (p = 0.95) or LMM (57%) (p = 0.41) subtypes.
DISCUSSION
The findings of higher mitosis rates in relatively thin 
(≤ 2 mm) NM compared with other subtypes (with the 
possible exception of LMM) support the hypothesis that 
primary NM is a histopathologic entity from the outset. 
The reason that the clear difference with LMM was not 
significant was most likely due to chance because of the 
small numbers of LMM cases (n = 48) compared with 
say SSM (n = 740), given that the distributions of mito-
tic rate, thickness > 4 mm and ulceration in LMM and 
other subtypes were almost identical. The similar mitotic 
rates across melanomas thicker than 2 mm regardless of 
subtype may reflect the erasing of radial growth phase 
by advanced melanomas and their convergence to thick, 
invasive tumours fitting the criteria for NM (11, 12). 
That it is among melanomas up to 2 mm thick where 
the nodular subtype is distinctive in its rapid growth rate 
is consistent with other large population series (9), and 
suggests the poor prognosis cannot be explained solely 
by greater measured thickness. These findings were borne 
out by actual survival data for the Australian patients with 
a mean 4.6 years follow-up, showing that patients with 
thin (up to 2 mm) NMs have substantially lower DFS 
compared with SSM and LMM of the same thickness, 
whereas there were no differences in DFS according to 
melanoma subtype among those with thicker melanomas.
The strength of this study is its large sample size and 
the inclusion of two international series. Its weakness 
is the lack of standardised reporting of histopathologic 
subtypes. Main differences were in the proportions of 
SSM (43% England, 57% Australia) and unknown (8% 
England, 15% Australia) subtypes, though proportions of 
NMs were almost the same (24% England, 22% Austra-
lia). We conclude that recognition of NM as a high-risk 
histopathologic entity is clinically most important for 
thinner (< 2 mm) melanomas. Since the vast majority of 
today’s melanomas are thin when diagnosed, identifica-
tion of NM should remain a valuable aid to clinicians to 
predict outcome and guide patient management.  
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